237 related articles for article (PubMed ID: 29331774)
1. The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia.
Zhao H; Zhu H; Huang J; Zhu Y; Hong M; Zhu H; Zhang J; Li S; Yang L; Lian Y; Wang S; Mao J; Chen Y; Li J; Qian S
Leuk Res; 2018 Mar; 66():1-7. PubMed ID: 29331774
[TBL] [Abstract][Full Text] [Related]
2. Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
Huang J; Hong M; Zhu Y; Zhao H; Zhang X; Wu Y; Lian Y; Zhao X; Li J; Qian S
Leuk Lymphoma; 2018 Nov; 59(11):2570-2579. PubMed ID: 29616840
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
[TBL] [Abstract][Full Text] [Related]
4. Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Zhu Y; Zhao H; Zhang X; Wu Y; Xie Y; Li Y; Lian Y; Huang J; Li J; Chen Y; Qian S
Biol Blood Marrow Transplant; 2017 May; 23(5):830-835. PubMed ID: 28189902
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia.
Dou L; Xu Q; Wang M; Xiao Y; Cheng L; Li H; Huang W; Mei J; Jing Y; Bo J; Liu D; Yu L
Onco Targets Ther; 2019; 12():5013-5023. PubMed ID: 31303761
[No Abstract] [Full Text] [Related]
6. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
[TBL] [Abstract][Full Text] [Related]
7. Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia.
Wang B; Guan W; Lv N; Li T; Yu F; Huang Y; Wang Y; Li L; Yu L
Hematology; 2021 Dec; 26(1):371-379. PubMed ID: 33971800
[TBL] [Abstract][Full Text] [Related]
8. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
Zhang JL; Cao YP; Li JG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):494-503. PubMed ID: 30998160
[TBL] [Abstract][Full Text] [Related]
10. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
[TBL] [Abstract][Full Text] [Related]
11. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy, Prognosis and Safety of Decitabine Combined with Low-Dose Cytarabine in the Treatment of Elderly Patients with Relapsed/Refractory Acute Myeloid Leukemia].
Chen D; Lu Y; Yan RZ; Ye PP; Zhang YS; Ma JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):390-395. PubMed ID: 30998143
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of 10-day decitabine in acute myeloid leukemia.
Bouligny IM; Mehta V; Isom S; Ellis LR; Bhave RR; Howard DS; Lyerly S; Manuel M; Dralle S; Powell BL; Pardee TS
Leuk Res; 2021 Apr; 103():106524. PubMed ID: 33640708
[TBL] [Abstract][Full Text] [Related]
14. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
Li X; Dong Y; Li Y; Ren R; Wu W; Zhu H; Zhang Y; Hu J; Li J
BMC Cancer; 2019 Aug; 19(1):819. PubMed ID: 31429724
[TBL] [Abstract][Full Text] [Related]
15. Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy.
Ni J; Hong J; Long Z; Li Q; Xia R; Zeng Q
Int J Lab Hematol; 2020 Dec; 42(6):849-857. PubMed ID: 32730663
[TBL] [Abstract][Full Text] [Related]
16. Analysis of TET2 and EZH2 gene functions in chromosome instability in acute myeloid leukemia.
Wang J; He N; Wang R; Tian T; Han F; Zhong C; Zhang C; Hua M; Ji C; Ma D
Sci Rep; 2020 Feb; 10(1):2706. PubMed ID: 32066746
[TBL] [Abstract][Full Text] [Related]
17. Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML.
Hong M; Zhu H; Sun Q; Zhu Y; Miao Y; Yang H; Qiu HR; Li JY; Qian SX
Aging (Albany NY); 2020 Apr; 12(7):5792-5811. PubMed ID: 32238611
[TBL] [Abstract][Full Text] [Related]
18. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis.
Cao Y; Liu Y; Shang L; Wei W; Shen Y; Gu Q; Xie X; Dong W; Lin Y; Yue Y; Wang F; Gu W
Biomed Pharmacother; 2020 May; 125():109878. PubMed ID: 32006898
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
[No Abstract] [Full Text] [Related]
[Next] [New Search]
